Patent Law, Antitrust Enforcement, and Public Access to Pharmaceuticals and Medical Technologies

DSpace/Manakin Repository

Patent Law, Antitrust Enforcement, and Public Access to Pharmaceuticals and Medical Technologies

Citable link to this page

. . . . . .

Title: Patent Law, Antitrust Enforcement, and Public Access to Pharmaceuticals and Medical Technologies
Author: Sigman, Laura J.
Citation: Patent Law, Antitrust Enforcement, and Public Access to Pharmaceuticals and Medical Technologies (2003 Third Year Paper)
Full Text & Related Files:
Abstract: Patent and antitrust laws impact public access to pharmaceuticals and medical technologies. Two instances—one involving Roche’s new class of HIV/AIDS drugs, the other an antitrust action brought against Boston Scientific Corporation for violations of an anticompetitive agreement pertaining to cardiac treatment technology—illustrate the salient effects that medical products can have on public welfare. This paper provides a summary of patent laws, including provisions designed to advance the public interest, and explains the economic motivations underlying the patent regime. It also discusses the rationale behind antitrust laws and describes how courts account for public welfare when imposing damages for anticompetitive behavior. While it is difficult to assess the value of benefits and harm to the public, particularly where public health is concerned, legal regimes should aim to balance interests of producers and incentives for innovation with public needs for access to pharmaceuticals and medical devices.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852200

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters